



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/174056/2020

European Medicines Agency decision P/0137/2020

of 18 April 2020

on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (Ozempic) (EMA-001441-PIP01-13-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0137/2020

of 18 April 2020

on the acceptance of a modification of an agreed paediatric investigation plan for semaglutide (Ozempic) (EMA-001441-PIP01-13-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0095/2015 issued on 11 May 2015, the decision P/0334/2016 issued on 5 December 2016, and the decision P/0036/2019 issued on 29 January 2019,

Having regard to the application submitted by Novo Nordisk A/S on 27 November 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 February 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for semaglutide (Ozempic), solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novo Nordisk A/S, Vandtårnsvej 108-110, 2860 – Søborg, Denmark.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/12969/2020
Amsterdam, 28 February 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001441-PIP01-13-M03

Scope of the application

Active substance(s):

Semaglutide

Invented name:

Ozempic

Condition(s):

Treatment of type 2 diabetes mellitus

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Novo Nordisk A/S

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novo Nordisk A/S submitted to the European Medicines Agency on 27 November 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0095/2015 issued on 11 May 2015, the decision P/0334/2016 issued on 5 December 2016, and the decision P/0036/2019 issued on 29 January 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 6 January 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of type 2 diabetes mellitus

The waiver applies to:

- the paediatric population from birth to less than 10 years;
- solution for injection, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of type 2 diabetes mellitus

2.1.1. Indication(s) targeted by the PIP

Treatment of type 2 diabetes mellitus

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	3	Study 1 In <i>vitro</i> binding study to evaluate the potency of GLP-1 agonists semaglutide, exenatide and liraglutide on the rat GPL-1 receptor (14725-070). Study 2 Dose range-finding juvenile toxicity study to evaluate the influence of daily subcutaneous administration of semaglutide on the developing organism (214276).

		Study 3 Definitive juvenile toxicity study in the rat to evaluate the influence of daily subcutaneous administration of semaglutide on the developing organism (214479).
Clinical studies	1	Study 4 <i>(This study is the same as PIP Study 6 of semaglutide EMEA-001441-PIP02-15 for the oral tablet formulation, P/0217/2016 of 12/08/2016 and subsequent modifications thereof).</i> Randomised, 52-week, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy, safety and pharmacokinetics of semaglutide in paediatric patients from 10 to less than 18 years of age with type 2 diabetes mellitus as adjunct to diet and exercise and metformin, with or without concomitant basal insulin or diet and exercise and basal insulin alone.
Extrapolation, modelling and simulation studies	1	Study 5 Extrapolation study to simulation of average steady-state concentrations (C _{avg}) during s.c. semaglutide dose escalation and at maintenance dose for subjects 10 to less than 18 years with T2D using the same doses as applied in the adult phase 3a programme.
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of type 2 diabetes mellitus

Authorised indication(s):

- Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
 - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications,
 - in addition to other medicinal products for the treatment of diabetes.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Subcutaneous use.